Optimization of heroin conjugate vaccine performance in rodent models
- 1Laboratory of Adjuvant and Antigen Research, US Military HIV Research Program, Center for Military Infectious Diseases Research, Walter Reed Army Institute of Research
- 2Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Department of Health and Human Services
Abstract
Opioid use disorder (OUD) remains a global public health concern, exerting a significant economic burden on societies worldwide. To combat the rise of substance use disorder, a complementary vaccine-based intervention was developed to support and strengthen the existing treatment modalities. Hapten-protein conjugate vaccines are employed as a promising novel strategy for neutralizing nonimmunogenic small-molecule drugs such as opioids by eliciting drug-specific antibodies that sequester opioids in circulation before reaching the brain. In this study, multiple parameters to optimize the efficacy of the TT-6-AmHap heroin conjugate vaccine were investigated in mice and rats, focusing on dose optimization, hapten density, booster timing, and cross-reactivity with other prescription opioids. Binding antibody responses were quantified, and vaccine efficacy was assessed using nociceptive assays following a drug challenge. Immunization with TT-6-AmHap vaccine in combination with adjuvants ALF43 and Alhydrogel® (ALFA), demonstrated a robust in-vivo efficacy across multiple opioid challenges including heroin, hydrocodone, and hydromorphone. Both antibody titers to 6-AmHap and protective efficacy were maintained following repeated heroin challenges up to 54 weeks. Notably, these repeat heroin challenges did not induce any measurable decline in antibody titers. Further characterization of the vaccine responses indicated a strong correlation between hapten density on the carrier protein and both binding antibody titers and overall vaccine efficacy. These findings support the continued development of hapten-based conjugate vaccines for OUD and demonstrate that an optimized vaccine can provide long-lasting protection against the antinociceptive effects of opioids in animals, laying the groundwork for future translational studies.
Related
- Nasopharyngeal carriage of Streptococcus pneumoniae in children aged two to five years old in the conjugate vaccine era: A cross-sectional study in Salvador, Brazil
- Evaluating the impact and cost-effectiveness of typhoid conjugate vaccine schedules across diverse settings: A multi-model comparison
- Ketamine Modulates Endogenous Opioid Peptide Signaling and Reduces Heroin-Seeking in Male Long-Evans Rats
- A comparative evaluation of thiol/disulfide homeostasis and ischemia-modified albumin levels in patients with heroin use disorder in remission and detoxification
- Abstinence from heroin self-administration increases dendritic spine head diameter and the proportion of mushroom spines in rat prelimbic cortical neurons projecting to the paraventricular thalamus
BibTeX
@article{komla2026optimization,
title = {{Optimization of heroin conjugate vaccine performance in rodent models}},
author = {Essie Komla and Connor Whalen and Oscar B. Torres and Agnieszka Sulima and Arthur E. Jacobson and Kenner C. Rice and Gary R. Matyas},
journal = {npj Vaccines},
year = {2026},
month = jul,
doi = {10.1038/s41541-026-01517-6},
url = {https://doi.org/10.1038/s41541-026-01517-6},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Optimization of heroin conjugate vaccine performance in rodent models
AU - Essie Komla
AU - Connor Whalen
AU - Oscar B. Torres
AU - Agnieszka Sulima
AU - Arthur E. Jacobson
AU - Kenner C. Rice
AU - Gary R. Matyas
PY - 2026
DA - 2026/07/01
JO - npj Vaccines
DO - 10.1038/s41541-026-01517-6
UR - https://doi.org/10.1038/s41541-026-01517-6
AB - Opioid use disorder (OUD) remains a global public health concern, exerting a significant economic burden on societies worldwide. To combat the rise of substance use disorder, a complementary vaccine-based intervention was developed to support and strengthen the existing treatment modalities. Hapten-protein conjugate vaccines are employed as a promising novel strategy for neutralizing nonimmunogenic small-molecule drugs such as opioids by eliciting drug-specific antibodies that sequester opioids in circulation before reaching the brain. In this study, multiple parameters to optimize the efficacy of the TT-6-AmHap heroin conjugate vaccine were investigated in mice and rats, focusing on dose optimization, hapten density, booster timing, and cross-reactivity with other prescription opioids. Binding antibody responses were quantified, and vaccine efficacy was assessed using nociceptive assays following a drug challenge. Immunization with TT-6-AmHap vaccine in combination with adjuvants ALF43 and Alhydrogel® (ALFA), demonstrated a robust in-vivo efficacy across multiple opioid challenges including heroin, hydrocodone, and hydromorphone. Both antibody titers to 6-AmHap and protective efficacy were maintained following repeated heroin challenges up to 54 weeks. Notably, these repeat heroin challenges did not induce any measurable decline in antibody titers. Further characterization of the vaccine responses indicated a strong correlation between hapten density on the carrier protein and both binding antibody titers and overall vaccine efficacy. These findings support the continued development of hapten-based conjugate vaccines for OUD and demonstrate that an optimized vaccine can provide long-lasting protection against the antinociceptive effects of opioids in animals, laying the groundwork for future translational studies.
SN - 2059-0105
ER -